• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人工T细胞衔接分子转导的TCR-T细胞仅在以更高强度转导时才表现出增殖改善。

Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity.

作者信息

Sakai Toshiyasu, Terakura Seitaro, Miyao Kotaro, Okuno Shingo, Adachi Yoshitaka, Umemura Koji, Julamanee Jakrawadee, Watanabe Keisuke, Hamana Hiroshi, Kishi Hiroyuki, Leitner Judith, Steinberger Peter, Nishida Tetsuya, Murata Makoto, Kiyoi Hitoshi

机构信息

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Division of Clinical Hematology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.

出版信息

Mol Ther Oncolytics. 2020 Aug 28;18:613-622. doi: 10.1016/j.omto.2020.08.014. eCollection 2020 Sep 25.

DOI:10.1016/j.omto.2020.08.014
PMID:33005728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7509457/
Abstract

An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of T cell receptor (TCR) gene-transduced T (TCR-T) cells compared to such persistence in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain of 4-1BB inserted in the middle of CD3ζ. NY-ESO-1 TCR-T cells transduced with an ATAM with two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced TCR-T cells, we attempted to make a single virus vector to transduce the TCR and ATAM simultaneously. Because we failed to observe improved proliferation capacity upon stimulation after one virus vector (1vv) transduction, we compared TCR-T cells transduced with 1vv and two virus vector (2vv) methods to elucidate the reason. In Jurkat reporter cells, an ATAM transduced by the 2vv method demonstrated a higher intensity than by the 1vv method, and the ATAM intensity was associated with increased nuclear factor κB (NF-κB) signals upon stimulation. In ATAM-transduced primary T cells, a transduced ATAM by the 2vv method showed higher intensity and better proliferation. ATAM-transduced TCR-T cells demonstrated improved proliferation only when the ATAM was transduced at a higher intensity. To create a simpler transduction method, we need to develop a strategy to make a higher ATAM expression to prove the efficacy of ATAM transduction in TCR-T therapy.

摘要

为了提高T细胞受体(TCR)基因转导的T(TCR-T)细胞的持久性,我们构建了一种人工T细胞衔接分子(ATAM),并将其与之前研究中的持久性进行了比较。ATAM是经过基因修饰的CD3ζ,其细胞内结构域插入了4-1BB的中间部分。用两种分离的病毒载体转导ATAM的NY-ESO-1 TCR-T细胞在抗原刺激下表现出卓越的增殖能力。为了进一步开发临床适用的ATAM转导的TCR-T细胞,我们试图构建一种单一病毒载体来同时转导TCR和ATAM。由于在单病毒载体(1vv)转导后刺激时未观察到增殖能力的提高,我们比较了用1vv和双病毒载体(2vv)方法转导的TCR-T细胞,以阐明原因。在Jurkat报告细胞中,2vv方法转导的ATAM比1vv方法表现出更高的强度,并且刺激后ATAM强度与核因子κB(NF-κB)信号增加相关。在ATAM转导的原代T细胞中,2vv方法转导的ATAM表现出更高的强度和更好的增殖。只有当ATAM以更高强度转导时,ATAM转导的TCR-T细胞才表现出增殖改善。为了创建更简单的转导方法,我们需要开发一种策略来实现更高的ATAM表达,以证明ATAM转导在TCR-T治疗中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/6b90c942e1aa/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/92d5c5bcc634/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/32fc4bb28956/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/0c9d82dcc5cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/67a658921153/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/6694a9aa0af5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/6b90c942e1aa/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/92d5c5bcc634/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/32fc4bb28956/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/0c9d82dcc5cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/67a658921153/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/6694a9aa0af5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e24/7509457/6b90c942e1aa/gr5.jpg

相似文献

1
Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity.人工T细胞衔接分子转导的TCR-T细胞仅在以更高强度转导时才表现出增殖改善。
Mol Ther Oncolytics. 2020 Aug 28;18:613-622. doi: 10.1016/j.omto.2020.08.014. eCollection 2020 Sep 25.
2
Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.基因修饰的 CD3ζ 可提高抗原特异性 CTL 的增殖和持久性。
Cancer Immunol Res. 2018 Jun;6(6):733-744. doi: 10.1158/2326-6066.CIR-17-0538. Epub 2018 Apr 13.
3
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.用NY-ESO-1抗原特异性TCR基因转导的原代人淋巴细胞可识别并杀伤多种人类肿瘤细胞系。
J Immunol. 2005 Apr 1;174(7):4415-23. doi: 10.4049/jimmunol.174.7.4415.
4
A rare population of tumor antigen-specific CD4CD8 double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.一种罕见的肿瘤抗原特异性 CD4CD8 双阳性 αβ T 淋巴细胞群体,为工程化治疗性 T 细胞提供了独特的 CD8 非依赖性 TCR 基因。
J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.
5
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.将一种HLA-DP4限制性的NY-ESO-1特异性T细胞受体转导至原代人CD4+淋巴细胞中。
J Immunother. 2006 Jul-Aug;29(4):398-406. doi: 10.1097/01.cji.0000203082.20365.7f.
6
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.为一项临床试验进行基因编程以建立持久的癌症靶向免疫系统的 IND 研究。
Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.
7
Crk adaptor proteins regulate CD3ζ chain phosphorylation and TCR/CD3 down-modulation in activated T cells.Crk衔接蛋白调节活化T细胞中CD3ζ链的磷酸化及TCR/CD3的下调。
Cell Signal. 2017 Aug;36:117-126. doi: 10.1016/j.cellsig.2017.04.022. Epub 2017 Apr 29.
8
Construction of retroviral vectors carrying human CD3 gamma cDNA and reconstitution of CD3 gamma expression and T cell receptor surface expression and function in a CD3 gamma-deficient mutant T cell line.携带人CD3γ cDNA的逆转录病毒载体构建以及在CD3γ缺陷型突变T细胞系中CD3γ表达、T细胞受体表面表达和功能的重建
Hum Gene Ther. 1997 Jun 10;8(9):1041-8. doi: 10.1089/hum.1997.8.9-1041.
9
TCR crosslinking promotes Crk adaptor protein binding to tyrosine-phosphorylated CD3ζ chain.TCR交联促进Crk衔接蛋白与酪氨酸磷酸化的CD3ζ链结合。
Biochem Biophys Res Commun. 2017 Jul 1;488(3):541-546. doi: 10.1016/j.bbrc.2017.05.082. Epub 2017 May 17.
10
Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.T细胞受体基因在修饰造血干细胞用于癌症基因治疗方面的潜在应用。
Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003.

引用本文的文献

1
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.宫颈癌肿瘤浸润淋巴细胞治疗的研究进展
Front Immunol. 2025 May 19;16:1524842. doi: 10.3389/fimmu.2025.1524842. eCollection 2025.
2
Current developments in T-cell receptor therapy for acute myeloid leukemia.急性髓系白血病T细胞受体疗法的当前进展
Blood Adv. 2025 Jun 24;9(12):3069-3089. doi: 10.1182/bloodadvances.2024014105.
3
Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.在基于细胞的免疫疗法中寻找潜在的靶点,以应对急性髓系白血病的挑战。

本文引用的文献

1
Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.了解 TCR 亲和力、抗原特异性和交叉反应性,以改善用于癌症免疫治疗的 TCR 基因修饰 T 细胞。
Cancer Immunol Immunother. 2019 Nov;68(11):1881-1889. doi: 10.1007/s00262-019-02401-0. Epub 2019 Oct 8.
2
T cell engineering for adoptive T cell therapy: safety and receptor avidity.T 细胞工程用于过继性 T 细胞疗法:安全性和受体亲和性。
Cancer Immunol Immunother. 2019 Oct;68(10):1701-1712. doi: 10.1007/s00262-019-02395-9. Epub 2019 Sep 21.
3
Gene editing for immune cell therapies.
Front Immunol. 2024 Sep 30;15:1460437. doi: 10.3389/fimmu.2024.1460437. eCollection 2024.
4
TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.过表达 c-Jun 的 TCR T 细胞在肝癌中具有更好的功能,改善了肿瘤浸润和持久性。
Front Immunol. 2023 May 4;14:1114770. doi: 10.3389/fimmu.2023.1114770. eCollection 2023.
5
Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.用于急性髓系白血病的抗原特异性TCR-T细胞:现状与挑战
Front Oncol. 2022 Mar 9;12:787108. doi: 10.3389/fonc.2022.787108. eCollection 2022.
6
Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.HLA Ⅱ类分子表达下调与异基因干细胞移植后复发相关,并改变抗原特异性 T 细胞的识别。
Int J Hematol. 2022 Mar;115(3):371-381. doi: 10.1007/s12185-021-03273-w. Epub 2022 Jan 17.
7
Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application.用于食管癌治疗的基因改造T细胞:一项有前景的临床应用。
Front Oncol. 2021 Nov 9;11:763806. doi: 10.3389/fonc.2021.763806. eCollection 2021.
基因编辑免疫细胞疗法。
Nat Biotechnol. 2019 Dec;37(12):1425-1434. doi: 10.1038/s41587-019-0137-8. Epub 2019 Jun 3.
4
Therapeutic application of the CRISPR system: current issues and new prospects.CRISPR 系统的治疗应用:当前问题与新展望。
Hum Genet. 2019 Jun;138(6):563-590. doi: 10.1007/s00439-019-02028-2. Epub 2019 May 21.
5
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.采用表达天然 TCR 的抗原特异性 T 细胞的过继免疫疗法。
Cancer Immunol Res. 2019 Apr;7(4):528-533. doi: 10.1158/2326-6066.CIR-18-0888.
6
A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo.体内无靶标或脱靶自身免疫反应的强效肿瘤反应性 p53 特异性单链 TCR。
Mol Ther. 2019 Jan 2;27(1):261-271. doi: 10.1016/j.ymthe.2018.11.006. Epub 2018 Nov 15.
7
Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.基因修饰的 CD3ζ 可提高抗原特异性 CTL 的增殖和持久性。
Cancer Immunol Res. 2018 Jun;6(6):733-744. doi: 10.1158/2326-6066.CIR-17-0538. Epub 2018 Apr 13.
8
Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.用于改进T细胞过继性免疫疗法的TALEN基因编辑靶向的精细且可预测的调控
Mol Ther Nucleic Acids. 2017 Dec 15;9:312-321. doi: 10.1016/j.omtn.2017.10.005. Epub 2017 Oct 14.
9
Transposons: Moving Forward from Preclinical Studies to Clinical Trials.转座子:从临床前研究迈向临床试验。
Hum Gene Ther. 2017 Nov;28(11):1087-1104. doi: 10.1089/hum.2017.128. Epub 2017 Aug 22.
10
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.WT1 特异性 T 细胞受体基因转导的淋巴细胞在 AML 和 MDS 患者中的安全性和持久性。
Blood. 2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202. Epub 2017 Aug 31.